PROSper is a prospective cohort study of 100 women 35-50 years of age with BRCA 1/2 mutations who have elected to either undergo risk reducing salpingo-oophorectomy (RRSO) or nonsurgical management. The investigators will compare the change in cardiovascular health, bone health, sexual function, quality of life, and menopausal symptoms over 3 years of follow-up between women who undergo RRSO (baseline just prior to surgery) and age-matched controls that do not undergo RRSO. The investigators hypothesis is that women who undergo a premature surgical menopause induced by RRSO have worse cardiovascular health and bone health compared with women who do not undergo RRSO.
BRCA1 Gene MutationBRCA2 Gene Mutation
You can join if…
Open to females ages 35–50
BRCA mutation 1/2 or "Variant suspected deleterious" mutation.
Age 35-50 years
Able to undergo RRSO
Able to give informed consent
You CAN'T join if...
Prior history of bilateral oophorectomy
BRCA 1/2 deleterious mutation
Plans to move out of geographic region in next 3 years
Unable to travel to study visits
University of California, San Francisco San Francisco, California, 94115, United States